How long after taking omeprazole should a patient take Cymbalta (duloxetine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Timing of Omeprazole and Cymbalta (Duloxetine) Administration

There is no specific time interval required between taking omeprazole and Cymbalta (duloxetine), and they can be taken together without separation. The enteric-coated formulation of Cymbalta is designed to withstand gastric pH changes, and omeprazole does not affect duloxetine absorption or metabolism 1, 2.

Key Evidence Supporting Concurrent Administration

No pH-Dependent Absorption Issues

Research demonstrates that increases in gastric pH produced by H2-receptor antagonists or antacids did not impact the absorption of duloxetine 2. Since omeprazole works through a similar mechanism (reducing gastric acid), it does not interfere with duloxetine's enteric coating or absorption profile.

Metabolic Pathway Considerations

The primary concern with duloxetine drug interactions involves CYP1A2 inhibitors (which can increase duloxetine exposure by 460%) and CYP2D6 substrates 2. Omeprazole is metabolized primarily by CYP2C19 and CYP3A4, with minimal involvement of CYP1A2 or CYP2D6, making clinically significant pharmacokinetic interactions unlikely.

Practical Administration Guidance

Patients can take both medications at the same time of day without spacing them apart. Consider these practical points:

  • Cymbalta must be swallowed whole and cannot be opened, crushed, or chewed to preserve the enteric coating 1
  • Both medications can be taken with or without food
  • If the patient experiences nausea from duloxetine (a common side effect), taking it with food may help 3

Important Monitoring Considerations

While timing separation is unnecessary, be aware of:

  • Duloxetine can rarely cause acid reflux (reported in 1.38% of patients), which might paradoxically increase omeprazole requirements 4
  • The combination may be flagged by screening systems as a potential drug-drug interaction, but this represents a medication-review signal rather than confirmed clinical harm 5
  • Monitor for duloxetine's common adverse effects (nausea, dizziness, sedation) which are unrelated to omeprazole co-administration 3, 6

Clinical Pitfall to Avoid

Do not confuse this situation with CYP1A2 inhibitors like fluvoxamine, which require dose adjustment or avoidance with duloxetine 2. Omeprazole does not share this interaction profile and requires no special timing or dosing modifications when used with Cymbalta.

References

Research

Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2005

Related Questions

What is the recommended duloxetine dosing regimen, including starting dose, titration schedule, maximum dose, and adjustments for hepatic or renal impairment and elderly patients?
Can duloxetine (Cymbalta) be taken twice daily?
What are the dosing guidelines, contraindications, and monitoring recommendations for duloxetine (Cymbalta)?
Is Cymbalta (duloxetine) a selective serotonin reuptake inhibitor (SSRI)?
Could duloxetine (Cymbalta) be causing my hair-picking behavior, and what management steps should I take?
What is the appropriate influenza B vaccine dose and administration method for a patient who is post‑splenectomy and has hemophilia?
In an adult with type 2 diabetes, when and how should ACE‑inhibitor therapy be initiated, dosed, and monitored?
What is the recommended treatment for acute otitis media in otherwise healthy adults?
Compare the two laboratory panels (first: glucose 163 mg/dL, blood urea nitrogen 29 mg/dL, creatinine 0.6 mg/dL, BUN‑to‑creatinine ratio 50, sodium 130 mmol/L, potassium 4.4 mmol/L, chloride 97 mmol/L, CO₂ 27 mmol/L, calcium 8.9 mg/dL, estimated glomerular filtration rate >90 mL/min/1.73 m²; second: glucose 184 mg/dL, blood urea nitrogen 26 mg/dL, creatinine 0.5 mg/dL, BUN‑to‑creatinine ratio 55, sodium 135 mmol/L, potassium 4.3 mmol/L, chloride 103 mmol/L, CO₂ 25 mmol/L, calcium 9.2 mg/dL, estimated glomerular filtration rate >90 mL/min/1.73 m²) to assess dehydration?
How should aplastic anemia be managed with eltrombopag (Promacta) and cyclosporine?
What is the first-line management for a patient with chronic venous insufficiency?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.